分子肿瘤委员会在癌症患者管理中的作用（意大利南部经验）表1数据集

数据集获取（Figshare）

• 源站标题：Table_1_The molecular tumor board as a step in cancer patient management: a southern Italian experience.xlsx
• DOI：10.3389/fmed.2024.1432628.s001
• 发布日期：2024-10-25
• 文件数：1 个
• 文件总体积：49.51 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Table_1_The_molecular_tumor_board_as_a_step_in_cancer_patient_management_a_southern_Italian_experience_xlsx/27302493

命令行下载

curl -L -o "Table_1_The molecular tumor board as a step in cancer patient management: a southern Italian experience.xlsx" "https://ndownloader.figshare.com/files/49991712"

文件清单

• Table_1_The molecular tumor board as a step in cancer patient management: a southern Italian experience.xlsx（49.51 KB）

文件总体积 49.51 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

IntroductionThe management of cancer patients follows a Diagnostic Therapeutic and Care Pathway (PDTA) approach, aimed at achieving the optimal balance between care and quality of life. To support this process, precision medicine and innovative technologies [e.g., next-generation sequencing (NGS)] allow rapid identification of genetic-molecular alterations useful for the design of PDTA-approved therapies. If the standard approach proves inadequate, the Molecular Tumor Board (MTB), a group comprising specialists from diverse disciplines, can step in to evaluate a broader molecular profile, proposing potential therapies beyond evidence levels I–II or considering enrolment in clinical trials. Our aim is to analyze the role of the MTB in the entire management of patients in our institute and its impact on the strategy of personalized medicine, particularly when all approved treatments have failed.
Materials and methodsIn alignment with European and national guidelines, a panel of clinicians and preclinical specialists from our institution was defined as the MTB core team. We designed and approved a procedure for the operation of this multidisciplinary group, which is the only one operating in the Puglia region.
Results and discussionIn 29 months (2021–2023), we discussed and analyzed 93 patients. A total of 44% presented pathogenic alterations, of which 40.4% were potentially actionable. Only 11 patients were proposed for enrollment in clinical trials, treatment with off-label drugs, or AIFA (the Italian pharmaceutical agency for drugs)—5% funding. Our process indicators, time to analysis, and number of patient cases discussed are in line with the median data of other European institutions. Such findings underscore both the importance and usefulness of the integration of an MTB process into the care of oncology patients.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fmed.2024.1432628.s001（source: https://frontiersin.figshare.com/articles/dataset/Table_1_The_molecular_tumor_board_as_a_step_in_cancer_patient_management_a_southern_Italian_experience_xlsx/27302493）。